13.29
price up icon2.23%   0.29
after-market Handel nachbörslich: 13.53 0.24 +1.81%
loading
Schlusskurs vom Vortag:
$13.00
Offen:
$12.935
24-Stunden-Volumen:
4.53M
Relative Volume:
3.45
Marktkapitalisierung:
$495.88M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-2.0509
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
+44.93%
1M Leistung:
-2.99%
6M Leistung:
+101.36%
1J Leistung:
+184.58%
1-Tages-Spanne:
Value
$12.80
$14.98
1-Wochen-Bereich:
Value
$8.95
$14.98
52-Wochen-Spanne:
Value
$3.73
$19.18

Uniqure N V Stock (QURE) Company Profile

Name
Firmenname
Uniqure N V
Name
Telefon
1-339-970-7000
Name
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Name
Mitarbeiter
0
Name
Twitter
@uniQure_NV
Name
Nächster Verdiensttermin
2024-07-30
Name
Neueste SEC-Einreichungen
Name
QURE's Discussions on Twitter

Vergleichen Sie QURE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
QURE
Uniqure N V
13.29 495.88M 15.84M -308.48M -153.08M -6.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Uniqure N V Stock (QURE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-01 Fortgesetzt Chardan Capital Markets Buy
2024-12-10 Hochstufung Raymond James Outperform → Strong Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-02-29 Herabstufung Goldman Buy → Neutral
2023-12-19 Herabstufung Mizuho Buy → Neutral
2022-03-17 Hochstufung UBS Neutral → Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-05-21 Eingeleitet UBS Neutral
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-04-01 Hochstufung Mizuho Neutral → Buy
2021-01-07 Hochstufung Guggenheim Neutral → Buy
2020-11-24 Eingeleitet H.C. Wainwright Buy
2020-11-11 Eingeleitet Berenberg Buy
2020-11-09 Eingeleitet Jefferies Buy
2020-11-04 Eingeleitet Cantor Fitzgerald Overweight
2020-10-23 Eingeleitet RBC Capital Mkts Outperform
2020-08-25 Eingeleitet Raymond James Strong Buy
2020-07-31 Hochstufung Robert W. Baird Neutral → Outperform
2020-06-25 Herabstufung Mizuho Buy → Neutral
2020-06-25 Herabstufung Robert W. Baird Outperform → Neutral
2020-06-25 Herabstufung Wells Fargo Overweight → Equal Weight
2019-12-03 Eingeleitet Cowen Outperform
2019-12-03 Eingeleitet Goldman Buy
2019-11-05 Eingeleitet Credit Suisse Outperform
2019-10-11 Eingeleitet Stifel Buy
2019-09-25 Eingeleitet Bernstein Outperform
2019-09-12 Eingeleitet Mizuho Buy
2019-07-30 Herabstufung Guggenheim Buy → Neutral
2019-07-08 Bestätigt Cantor Fitzgerald Overweight
2019-04-12 Eingeleitet Piper Jaffray Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Uniqure N V Aktie (QURE) Neueste Nachrichten

pulisher
01:50 AM

Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha

01:50 AM
pulisher
09:54 AM

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance

09:54 AM
pulisher
07:30 AM

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha

07:30 AM
pulisher
01:56 AM

uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha

01:56 AM
pulisher
Apr 19, 2025

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha

Apr 19, 2025
pulisher
Apr 18, 2025

uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN

Apr 17, 2025
pulisher
Apr 17, 2025

FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure shares soar on FDA breakthrough therapy designation - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | QURE Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World

Apr 17, 2025
pulisher
Apr 17, 2025

Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com

Apr 17, 2025
pulisher
Apr 16, 2025

uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 16, 2025

JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World

Apr 16, 2025
pulisher
Apr 16, 2025

uniQure CEO secures amended employment agreement - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

uniQure Amends CEO Employment Agreement - TipRanks

Apr 16, 2025
pulisher
Apr 15, 2025

Alliancebernstein L.P. Has $3.60 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

NEVADA KING ANNOUNCES INCREASE OF PHASE III PROGRAM TO 30,000M, REFINES REGIONAL TARGETS AT ATLANTA - The Globe and Mail

Apr 14, 2025
pulisher
Apr 06, 2025

Institutional owners may ignore uniQure N.V.'s (NASDAQ:QURE) recent US$190m market cap decline as longer-term profits stay in the green - simplywall.st

Apr 06, 2025
pulisher
Apr 06, 2025

(QURE) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 02, 2025

uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital - The AM Reporter

Apr 02, 2025
pulisher
Mar 31, 2025

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com

Mar 31, 2025
pulisher
Mar 26, 2025

Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 25, 2025

Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com

Mar 25, 2025
pulisher
Mar 16, 2025

(QURE) Trading Report - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 13, 2025

uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 09, 2025

Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

uniQure Reports 2024 Financial Results and Progress - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa

Mar 05, 2025

Finanzdaten der Uniqure N V-Aktie (QURE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):